IO Biotech Analyst Ratings
IO Biotech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 451.72% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 08/15/2023 | 382.76% | Morgan Stanley | $11 → $7 | Maintains | Overweight |
| 08/11/2023 | 451.72% | HC Wainwright & Co. | $11 → $8 | Reiterates | Buy → Buy |
| 03/15/2023 | 589.66% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 01/24/2023 | 658.62% | Morgan Stanley | $15 → $11 | Maintains | Overweight |
| 11/21/2022 | 589.66% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 11/30/2021 | 1348.28% | Morgan Stanley | → $21 | Initiates Coverage On | → Overweight |
| 11/30/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/30/2021 | 1279.31% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/13/2023 | 451.72% | HC Wainwright公司 | →$8 | 重申 | 購買→購買 |
| 2023年08月15日 | 382.76% | 摩根士丹利 | $11→$7 | 維護 | 超重 |
| 2023年08月11日 | 451.72% | HC Wainwright公司 | $11→$8 | 重申 | 購買→購買 |
| 03/15/2023 | 589.66% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 01/24/2023 | 658.62% | 摩根士丹利 | $15→$11 | 維護 | 超重 |
| 2022年11月21日 | 589.66% | HC Wainwright公司 | →$10 | 開始承保 | →購買 |
| 2021年11月30日 | 1348.28% | 摩根士丹利 | →$21 | 開始承保 | →超重 |
| 2021年11月30日 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2021年11月30日 | 1279.31% | 傑富瑞 | →$20 | 開始承保 | →購買 |
What is the target price for IO Biotech (IOBT)?
IO Biotech(IOBT)的目標價是多少？
The latest price target for IO Biotech (NASDAQ: IOBT) was reported by HC Wainwright & Co. on September 13, 2023. The analyst firm set a price target for $8.00 expecting IOBT to rise to within 12 months (a possible 451.72% upside). 6 analyst firms have reported ratings in the last year.
IO Biotech(納斯達克代碼：IOBT)的最新目標價是由HC Wainwright&Co.於2023年9月13日報道的。這家分析公司將目標價定為8美元，預計IOBT將在12個月內升至(可能上漲451.72%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for IO Biotech (IOBT)?
IO Biotech(IOBT)的最新分析師評級是多少？
The latest analyst rating for IO Biotech (NASDAQ: IOBT) was provided by HC Wainwright & Co., and IO Biotech reiterated their buy rating.
IO Biotech(納斯達克代碼：IOBT)的最新分析師評級由HC Wainwright&Co.提供，IO Biotech重申其買入評級。
When is the next analyst rating going to be posted or updated for IO Biotech (IOBT)?
IO Biotech(IOBT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IO Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IO Biotech was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與IO Biotech的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。IO Biotech的上一次評級是在2023年9月13日提交的，所以你應該預計下一次評級將在2024年9月13日左右的某個時候公佈。
Is the Analyst Rating IO Biotech (IOBT) correct?
分析師對IO Biotech(IOBT)的評級正確嗎？
While ratings are subjective and will change, the latest IO Biotech (IOBT) rating was a reiterated with a price target of $0.00 to $8.00. The current price IO Biotech (IOBT) is trading at is $1.45, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的IO Biotech(IOBT)評級被重申，目標價在0.00美元至8.00美元之間。IO Biotech(IOBT)目前的交易價格為1.45美元，在分析師的預測區間內。